How the Stock Market Works: Intel, IBM & AI Chip Deals

When the Market Drops, the Real Stories Begin

A 500-point Dow selloff grabs headlines. But for investors who understand how the stock market works, the noise is less interesting than the signal underneath it. On any given red day, you'll find companies up 10%, others down 14%, and deals being struck that will quietly reshape entire industries over the next decade.

That's exactly what a recent wave of market action illustrated. Intel surged on foundry progress. Amgen cratered on a rival's failed drug trial. Amazon and Qualcomm announced a chip partnership that cuts to the heart of the AI arms race. And IBM — a company many investors have written off for years — is sitting at a price point that at least one analyst believes is significantly undervalued.

Here's what each of these stories actually means, stripped of the short-term panic and examined through the lens of fundamentals.

Intel's Foundry Bet: Why Manufacturing Matters as Much as Design

Intel shares jumped over 10% after the company announced it had processed more than 1 million wafers using high-NA EUV (Extreme Ultraviolet Lithography) technology — a milestone that sounds technical but carries serious strategic weight.

Here's the context: Intel's turnaround strategy isn't just about making better chips for its own products. It's about becoming a contract manufacturer — a foundry — for other companies that design chips but don't want to build their own fabrication plants. This is the business model that made TSMC, Taiwan Semiconductor Manufacturing Company, one of the most strategically critical companies on earth.

For Intel to compete in that space, it needs to demonstrate it can manufacture at scale, reliably, and at the leading edge of chip geometry. The 1 million wafer milestone is a signal that the production process is maturing.

Why this matters for investors:

• Intel's foundry ambitions give it a second revenue engine beyond its own chip sales
• The AI boom is creating enormous demand for custom silicon — demand that TSMC alone may not be able to satisfy
• Intel at current levels (~$105 per share) is still well below its peak of ~$142, meaning the market hasn't fully priced in a successful turnaround
• The risk is real: foundry customers need confidence, and Intel is still proving itself

The stock went from ~$17 at its low roughly 18 months ago to over $100. That's not a recovery — that's a repositioning. Investors should watch customer acquisition in the foundry division as the clearest signal of whether this strategy is working.

Amgen's Pipeline Problem: What Drug Company Investors Must Understand

Amgen fell nearly 10% — not because of anything Amgen did, but because Novartis announced that its experimental cardiovascular drug pelcasiran failed to meet its primary endpoint in a Phase 3 clinical trial.

This is a textbook example of how interconnected pharmaceutical markets are. Amgen has its own cardiovascular drug, olpasiran, with Phase 3 data expected around mid-2028. When Novartis's similar compound failed, the market immediately questioned whether Amgen's drug faces comparable scientific headwinds.

Understanding how the stock market works in pharma:

• Drug companies derive enormous value from their pipeline — not just approved drugs, but compounds in development
• A Phase 3 failure is the most expensive kind: years of development, hundreds of millions spent, and the patent clock still ticking on other assets
• Spillover selloffs — where one company's failure tanks a competitor's stock — are common in biotech and pharma, and sometimes create buying opportunities if the underlying science differs

Amgen's financials are worth examining here. Free cash flow over the past 10 years has been remarkably stable — ranging from roughly $7.4 billion to $10.5 billion annually. That's not explosive growth, but it's consistent. The issue is capital expenditure, which has nearly quadrupled since 2019, and $33 billion in acquisitions over the past five years. Analysts project 5–8% annual growth, but the historical data doesn't clearly support that optimism.

At roughly 21 times free cash flow after the selloff, Amgen is cheaper than it was — but investors need a clear thesis on whether olpasiran can generate meaningful revenue, or whether the pipeline broadly justifies current pricing.

Amazon and Qualcomm: How AI Is Redrawing the Chip Industry

Qualcomm issued warrants to Amazon to acquire approximately 25 million shares — worth around $4 billion — as part of a deal to develop customised silicon for AWS (Amazon Web Services) across multiple product generations.

This is a revealing move that illustrates how the stock market works when one company's margins become a problem for everyone else.

Nvidia's gross margins have skyrocketed since the AI boom began, because for a period, they were essentially the only supplier of AI-grade GPUs at scale. That's a great position for Nvidia shareholders. For every company writing those checks, it's a structural cost problem.

The response? Build your own chips, or partner with manufacturers who can build them cheaper and faster.

The strategic logic here is clear:

• Amazon has the scale to justify custom silicon investment — AWS processes enormous workloads
• By issuing equity warrants to Amazon, Qualcomm aligns Amazon's financial interest with Qualcomm's success — Amazon now has an incentive to send chip orders to Qualcomm
• This mirrors a broader trend: Google has its TPUs, Apple designs its own silicon, Microsoft is developing custom AI chips. The era of pure Nvidia dependency is already ending at the top

For investors, the long-term read is that Nvidia's market share, while still dominant, will face structural compression from this wave of vertical integration. Companies with foundry capabilities — like Intel — and fabless designers with strong customer relationships — like Qualcomm — are potentially well-positioned.

IBM: Old Company, Interesting Math — How to Value a Business Properly

IBM is one of the most written-off companies in technology. The stock has roughly doubled over 15 years — underwhelming compared to almost any high-growth tech benchmark. Yet at least one analyst argues it's meaningfully undervalued, and the reasoning is worth understanding because it demonstrates fundamental valuation thinking.

The argument runs roughly as follows: IBM's software, consulting, and infrastructure businesses, valued conventionally, suggest an equity value around $281 per share. The stock trades at approximately $231. That gap implies you're buying those businesses at a discount — and getting IBM's quantum computing ambitions essentially for free as a speculative upside.

This is a classic "sum of the parts" valuation approach, and it's a useful framework for any investor learning how the stock market works.

The IBM numbers in context:

• Market cap: approximately $220 billion
• Enterprise value: approximately $330 billion
• The $110 billion difference is debt — significant for a company generating $11.5 billion in average annual free cash flow over five years
• Dividend payments consume roughly $6.3 billion of that free cash flow annually
• Returns on capital are low — a warning sign that the business isn't compounding efficiently

Running conservative assumptions through a discounted cash flow model — revenue growth of 2–6% over 10 years, free cash flow margins of 15–20%, and a price-to-free-cash-flow exit multiple of 13–19x — generates an intrinsic value range of approximately $140 to $310, with a midpoint around $210.

At today's price of ~$231, IBM looks roughly fairly valued on middle assumptions, implying an expected return of around 8% annually including the dividend. That's not compelling, but it's not a disaster either — and if the quantum computing thesis has any validity, the upside skews higher.

The debt load is the real concern. $110 billion in debt against $11–14 billion in annual free cash flow means IBM has limited flexibility. Any revenue shock, rate spike, or acquisition misstep could tighten that position quickly.

The Big Picture: Are Markets Actually Overvalued?

Zooming out, the Buffett Indicator — total stock market capitalisation divided by GDP — currently sits at approximately 143% above its historical fair value. The Shiller CAPE (Cyclically Adjusted Price-to-Earnings) ratio, which smooths earnings over 10 years to remove cyclical distortion, points to the market being roughly 131% overvalued.

These aren't trading signals. Markets can remain expensive for years, and overvaluation alone is not a reason to exit equities. But they are important context for expected return calculations.

What this means practically:

• Investors entering the market at these valuations should model for lower expected returns over the next decade — perhaps 4–6% annually rather than the historical 10%
• Stock selection matters more in expensive markets, because there's less tide to lift all boats
• Companies with strong free cash flow, low debt, and reasonable valuations become relatively more attractive when the broad market is priced for perfection

This is precisely why running the numbers on individual companies — rather than buying index funds and hoping — becomes more valuable in elevated-valuation environments. Not as a rejection of diversification, but as a discipline for knowing what you own and what you're paying for it.

Practical Takeaways for Investors

Here's what the day's market action actually teaches, applied as durable principles:

• Short-term noise is irrelevant. Oil prices, daily Dow moves, and Fed rate speculation don't determine long-term returns. Free cash flow, competitive position, and price paid do.
• Pipeline risk in pharma is structural. If a drug company's growth thesis depends on unproven compounds, price accordingly — demand a significant discount to account for binary outcomes.
• High margins attract competition. Nvidia's GPU margins are drawing billions in competing investment. Any company with unsustainably high margins should be modelled with compressing margins over time.
• Debt changes everything. Two companies with identical earnings profiles but different debt loads are fundamentally different investments. Always look at enterprise value, not just market cap.
• Valuation isn't just about growth. A slow-growing, cash-generative business at the right price can outperform a fast-growing business at the wrong one. The price you pay determines the return you get.

Understanding how the stock market works isn't about predicting tomorrow's moves. It's about building a repeatable process for separating price from value — and having the patience to act only when the gap between them is large enough to matter.

Frequently Asked Questions

How does the stock market work for beginners?

The stock market is a marketplace where investors buy and sell ownership stakes (shares) in publicly listed companies. Share prices fluctuate based on supply and demand, which is influenced by company earnings, economic data, interest rates, and investor sentiment. For beginners, the most important concept is that a share represents a fractional ownership of a real business — so the underlying financial health of that business, not the daily price movement, is what drives long-term returns.

Why do pharmaceutical stocks sometimes fall when a competitor's drug fails?

This happens because drug companies in the same therapeutic area are often working on similar mechanisms or targets. When one drug fails a clinical trial, the market infers that the underlying science may have broader problems — affecting all companies pursuing similar treatments. This is called a "read-across" event. Sometimes the selloff is justified; sometimes it creates a buying opportunity if the competing compound uses a meaningfully different approach.

What is the Buffett Indicator and why does it matter?

The Buffett Indicator is the ratio of total stock market capitalisation to GDP. Warren Buffett has described it as "probably the best single measure of where valuations stand at any given moment." When the ratio is significantly above 100%, the market is considered expensive relative to the economy's productive capacity. It doesn't predict when a correction will occur, but historically, high readings have been associated with below-average returns over the following decade.

What is a foundry business in the semiconductor industry?

A semiconductor foundry is a company that manufactures chips designed by other firms. Companies like Apple, Amazon, and Qualcomm design their own chips but outsource manufacturing to foundries — most notably TSMC. Intel's foundry strategy involves opening its fabrication plants to outside customers, competing directly with TSMC and Samsung. Success in this business requires manufacturing precision, capacity, and the trust of customers who are often competitors in adjacent markets.

How should investors evaluate a company with high debt levels?

High debt isn't automatically bad — it depends on the company's ability to service that debt from operating cash flow. A useful starting point is comparing net debt to annual free cash flow. If a company carries $110 billion in debt and generates $12 billion in free cash flow, that's roughly a 9x leverage ratio — high enough to limit financial flexibility. Investors should also consider how much of that free cash flow is already committed to dividends or capital expenditure before debt repayment.

This article is for informational purposes only and does not constitute financial advice. Always consult a qualified financial professional before making investment decisions.